Literature DB >> 21598345

Distinguishing hemangiomas from malignant solid hepatic lesions: a comparison of heavily T2-weighted images obtained before and after administration of gadoxetic acid.

Sung Jun Ahn1, Myeong-Jin Kim, Hye-Suk Hong, Kyung Ah Kim, Ho-Taek Song.   

Abstract

PURPOSE: To compare the use of heavily T2-weighted images obtained before and after administration of gadoxetic acid in differentiating hemangiomas from malignant solid hepatic lesions.
MATERIALS AND METHODS: Heavily T2-weighted images (TE=150 msec) were obtained for 70 patients (42 men and 28 women) with 74 focal hepatic lesions (25 hepatocellular carcinomas [HCC], 22 metastases, and 27 hemangiomas) ≤3 cm in diameter before and after gadoxetic acid-enhanced dynamic magnetic resonance imaging (MRI). Quantitative analysis was performed using receiver operating characteristic (ROC) curves with lesion-to-liver signal intensity difference-to-noise ratio (SDNR) on precontrast and postcontrast images. Qualitative analysis was also performed by two blinded reviewers.
RESULTS: The SDNR of the solid lesions was significantly higher on the postcontrast (1.66 ± 1.18) than on the precontrast (1.38 ± 1.07) images (P=0.0012), while the SDNR of hemangiomas was comparable for pre- and postcontrast images (P=0.8164). The best SDNR cutoff values for distinguishing solid lesions from hemangiomas were ≤1.85 (Az=0.948) for precontrast and ≤2.58 (Az=0.901) for postcontrast images (P=0.057). Reader performances for distinguishing hemangiomas from solid lesions were comparable between the precontrast (Az=0.975 and 0.970 for readers 1 and 2) and postcontrast (Az=0.977 and 0.972) images (P=0.899 and 0.946).
CONCLUSION: Heavily T2-weighted images obtained after administration of gadoxetic acid have a diagnostic capability comparable to precontrast images for differentiating between small hemangiomas and malignant solid lesions of the liver.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21598345     DOI: 10.1002/jmri.22658

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

Review 1.  Magnetic Resonanance Imaging of the Liver (Including Biliary Contrast Agents)-Part 2: Protocols for Liver Magnetic Resonanance Imaging and Characterization of Common Focal Liver Lesions.

Authors:  Andrea Agostini; Moritz F Kircher; Richard K G Do; Alessandra Borgheresi; Serena Monti; Andrea Giovagnoni; Lorenzo Mannelli
Journal:  Semin Roentgenol       Date:  2016-05-30       Impact factor: 0.800

2.  Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI.

Authors:  Mustafa R Bashir; Steven R Breault; Ryan Braun; Richard K Do; Rendon C Nelson; Scott B Reeder
Journal:  Acad Radiol       Date:  2014-04-06       Impact factor: 3.173

Review 3.  Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.

Authors:  Hyo Jung Park; Nieun Seo; So Yeon Kim
Journal:  Korean J Radiol       Date:  2022-04-13       Impact factor: 7.109

Review 4.  Liver-specific agents for contrast-enhanced MRI: role in oncological imaging.

Authors:  Yee Liang Thian; Angela M Riddell; Dow-Mu Koh
Journal:  Cancer Imaging       Date:  2013-12-30       Impact factor: 3.909

5.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.

Authors:  Kyung Hee Lee; Jeong Min Lee; Ji Hoon Park; Jung Hoon Kim; Hee Sun Park; Mi Hye Yu; Jeong-Hee Yoon; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2013-11-05       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.